While these findings contribute to the understanding of glucocorticoid signaling in the glioblastoma microenvironment and highlight the potential of GILZ as a modulator of immunoregulatory pathways in cancer, it is important to note that the data are preliminary and based on in vitro analyses in a single cell line. The gene discussed is TSC22D3; the disease is cancer.